David Christianson co-founds Arginetix, Inc

Arginetix, Inc., a biopharmaceutical company dedicated to developing and commercializing novel therapeutic small molecule inhibitors of arginase, announced today that it has completed a $2.3 million initial financing. The financing was co-led by Quaker BioVentures and MedImmune Ventures. Other investors included Red Abbey Venture Partners, Maryland Health Care Product Development Corporation and Acidophil LLC. The company's scientific foundation is based on discoveries of the scientific co-founders, David Christianson, Ph.D. at the University of Pennsylvania and Dan Berkowitz M.D. at the Johns Hopkins University. (FierceBiotech.com)